RESTORE | User-centred smart nanobiomaterial-based 3D matrices for chondral repair

Summary
The RESTORE project aims at developing an effective approach to manage the specific unmet clinical needs to treat knee chondral lesions. RESTORE, built upon the consortium’s proofs-of-concept and discussions between orthopaedic surgeons, tissue engineers, material scientists, cell biologists and SMEs, will realize a new generation of smart nanoenabled 3D matrices able to fit into complex lesion geometry, modulate undesirable biological events, and remotely control, stimulate and monitor cartilage repair. To create smart and functional 3D matrices, RESTORE will develop (i) nanobiomaterial-based nanocarriers to modulate inflammatory, cartilage extracellular matrix degradation and infection threats, (ii) stimuli-responsive nanobiomaterials tuned via external physical stimulus using radiofrequency and electromagnetic fields, and (iii) non-invasive wearable and wireless device for remote stimulus and regeneration monitoring. The nanobiomaterials will be integrated into cutting-edge 3D matrices that meet the needs of severe and mild chondral lesions: 1) the COPLA Scaffold commercialised since 2017 for animal health use and 2) 3D cartilage microtissues engineered via 3D bioprinting of iPS cells in a nanocellulose and alginate bioink. The technology development in RESTORE will reach TRL5 and enable substantial clinical advances in regenerative medicine. Untreated or not-correctly treated chondral lesions are likely to progress towards osteoarthritis (OA), which affects 242 million people globally (costs/patient/year: 10,452€). RESTORE will address the shortfalls of current therapeutic solutions while aiming to reduce the overall burden of OA. RESTORE’s outcomes hold high exploitation and commercial potential to boost the competitiveness of European companies, striving to diminish or delay the onset of OA, reducing hospitalization, number of surgeon interventions and time off work, thus leading to more cost-efficient health care and promote wellbeing and active ageing.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/814558
Start date: 01-01-2019
End date: 31-08-2022
Total budget - Public funding: 5 539 736,00 Euro - 5 539 736,00 Euro
Cordis data

Original description

The RESTORE project aims at developing an effective approach to manage the specific unmet clinical needs to treat knee chondral lesions. RESTORE, built upon the consortium’s proofs-of-concept and discussions between orthopaedic surgeons, tissue engineers, material scientists, cell biologists and SMEs, will realize a new generation of smart nanoenabled 3D matrices able to fit into complex lesion geometry, modulate undesirable biological events, and remotely control, stimulate and monitor cartilage repair. To create smart and functional 3D matrices, RESTORE will develop (i) nanobiomaterial-based nanocarriers to modulate inflammatory, cartilage extracellular matrix degradation and infection threats, (ii) stimuli-responsive nanobiomaterials tuned via external physical stimulus using radiofrequency and electromagnetic fields, and (iii) non-invasive wearable and wireless device for remote stimulus and regeneration monitoring. The nanobiomaterials will be integrated into cutting-edge 3D matrices that meet the needs of severe and mild chondral lesions: 1) the COPLA Scaffold commercialised since 2017 for animal health use and 2) 3D cartilage microtissues engineered via 3D bioprinting of iPS cells in a nanocellulose and alginate bioink. The technology development in RESTORE will reach TRL5 and enable substantial clinical advances in regenerative medicine. Untreated or not-correctly treated chondral lesions are likely to progress towards osteoarthritis (OA), which affects 242 million people globally (costs/patient/year: 10,452€). RESTORE will address the shortfalls of current therapeutic solutions while aiming to reduce the overall burden of OA. RESTORE’s outcomes hold high exploitation and commercial potential to boost the competitiveness of European companies, striving to diminish or delay the onset of OA, reducing hospitalization, number of surgeon interventions and time off work, thus leading to more cost-efficient health care and promote wellbeing and active ageing.

Status

CLOSED

Call topic

NMBP-22-2018

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.2. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies
H2020-EU.2.1.2.0. INDUSTRIAL LEADERSHIP - Nanotechnologies - Cross-cutting call topics
H2020-NMBP-TR-IND-2018
NMBP-22-2018 Osteoarticular tissues regeneration (RIA)
H2020-EU.2.1.3. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
H2020-EU.2.1.3.0. Cross-cutting call topics
H2020-NMBP-TR-IND-2018
NMBP-22-2018 Osteoarticular tissues regeneration (RIA)